Malvaso, D.; Calabrese, L.; Chiricozzi, A.; Antonelli, F.; Coscarella, G.; Rubegni, P.; Peris, K.
IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa. Pharmaceutics 2023, 15, 2450.
https://doi.org/10.3390/pharmaceutics15102450
AMA Style
Malvaso D, Calabrese L, Chiricozzi A, Antonelli F, Coscarella G, Rubegni P, Peris K.
IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa. Pharmaceutics. 2023; 15(10):2450.
https://doi.org/10.3390/pharmaceutics15102450
Chicago/Turabian Style
Malvaso, Dalma, Laura Calabrese, Andrea Chiricozzi, Flaminia Antonelli, Giulia Coscarella, Pietro Rubegni, and Ketty Peris.
2023. "IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa" Pharmaceutics 15, no. 10: 2450.
https://doi.org/10.3390/pharmaceutics15102450
APA Style
Malvaso, D., Calabrese, L., Chiricozzi, A., Antonelli, F., Coscarella, G., Rubegni, P., & Peris, K.
(2023). IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa. Pharmaceutics, 15(10), 2450.
https://doi.org/10.3390/pharmaceutics15102450
